Summary:
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to
Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment
for the Negative Symptoms of Schizophrenia
Qualified Participants Must:
• Male or female,between 18 and 55 years of age at the time of Screening
Qualified Participants May Receive:
Compensation for time and gas